10 20 30 40 50 60 70 80 2PDX - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER OXIDOREDUCTASE 01-APR-07 2PDX
TITLE HUMAN ALDOSE REDUCTASE DOUBLE MUTANT S302R-C303D COMPLEXED TITLE 2 WITH ZOPOLRESTAT.
COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALDOSE REDUCTASE; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: AR, ALDEHYDE REDUCTASE; COMPND 5 EC: 1.1.1.21; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: ALR2; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21 GOLD; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET 15B
KEYWDS TIM BARREL, OXIDOREDUCTASE
EXPDTA X-RAY DIFFRACTION
AUTHOR H.STEUBER,A.HEINE,G.KLEBE
REVDAT 3 24-FEB-09 2PDX 1 VERSN REVDAT 2 01-JUL-08 2PDX 1 JRNL REVDAT 1 01-APR-08 2PDX 0
JRNL AUTH H.STEUBER,A.HEINE,A.PODJARNY,G.KLEBE JRNL TITL MERGING THE BINDING SITES OF ALDOSE AND ALDEHYDE JRNL TITL 2 REDUCTASE FOR DETECTION OF INHIBITOR JRNL TITL 3 SELECTIVITY-DETERMINING FEATURES. JRNL REF J.MOL.BIOL. V. 379 991 2008 JRNL REFN ISSN 0022-2836 JRNL PMID 18495158 JRNL DOI 10.1016/J.JMB.2008.03.063
REMARK 1
REMARK 2 REMARK 2 RESOLUTION. 1.65 ANGSTROMS.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.65 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 85.9 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.177 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.174 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.232 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.200 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 1691 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 32396 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.163 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.161 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.219 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.300 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 1400 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 26492 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2513 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 77 REMARK 3 SOLVENT ATOMS : 275 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 2849.00 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 2513.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 4 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 11491 REMARK 3 NUMBER OF RESTRAINTS : 10735 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 ANGLE DISTANCES (A) : 2.100 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.026 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.045 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.046 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.019 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.000 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.070 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.000 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC SCALING APPLIED BY THE REMARK 3 METHOD OF PARKIN, MOEZZI & HOPE, J.APPL.CRYST.28(1995)53-56
REMARK 4 REMARK 4 2PDX COMPLIES WITH FORMAT V. 3.15, 01-DEC-08
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 23-APR-07. REMARK 100 THE RCSB ID CODE IS RCSB042269.
REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 07-MAR-06 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU300 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 35600 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.650 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.5 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.07000 REMARK 200 R SYM (I) : 0.07000 REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 21.2000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.65 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.68 REMARK 200 COMPLETENESS FOR SHELL (%) : 56.0 REMARK 200 DATA REDUNDANCY IN SHELL : 2.10 REMARK 200 R MERGE FOR SHELL (I) : 0.46300 REMARK 200 R SYM FOR SHELL (I) : 0.46300 REMARK 200 <I/SIGMA(I)> FOR SHELL : 1.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: 1EL3 REMARK 200 REMARK 200 REMARK: NULL
REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 44.10 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.20 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20 % PEG 6000 IN 120 MM AMMONIUM REMARK 280 CITRATE, PH 5.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE REMARK 280 293K
REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 33.63000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE ASYMMETRIC UNIT CONTAINS ONE BIOLOGICAL MONOMER.
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 0 REMARK 465 GLU A 313 REMARK 465 GLU A 314 REMARK 465 PHE A 315
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 TYR A 209 CA - CB - CG ANGL. DEV. = 16.2 DEGREES REMARK 500 TYR A 209 CB - CG - CD1 ANGL. DEV. = 5.4 DEGREES REMARK 500 TYR A 209 CG - CD1 - CE1 ANGL. DEV. = 5.7 DEGREES REMARK 500 ARG A 217 NE - CZ - NH1 ANGL. DEV. = 3.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 21 0.12 81.32 REMARK 500 ALA A 299 115.78 178.83 REMARK 500 REMARK 500 REMARK: NULL
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NAP A 500 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ZST A 600
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2HVN RELATED DB: PDB REMARK 900 HUMAN ALDOSE REDUCTASE-ZOPOLRESTAT COMPLEX OBTAINED BY REMARK 900 COCRYSTALLISATION AFTER ONE DAY (1DAY_COCRYST) REMARK 900 RELATED ID: 2PDG RELATED DB: PDB REMARK 900 RELATED ID: 2PD5 RELATED DB: PDB REMARK 900 RELATED ID: 2PD9 RELATED DB: PDB REMARK 900 RELATED ID: 2PDB RELATED DB: PDB REMARK 900 RELATED ID: 2PDC RELATED DB: PDB REMARK 900 RELATED ID: 2PDF RELATED DB: PDB REMARK 900 RELATED ID: 2PDH RELATED DB: PDB REMARK 900 RELATED ID: 2PDI RELATED DB: PDB REMARK 900 RELATED ID: 2PDJ RELATED DB: PDB REMARK 900 RELATED ID: 2PDK RELATED DB: PDB REMARK 900 RELATED ID: 2PDL RELATED DB: PDB REMARK 900 RELATED ID: 2PDM RELATED DB: PDB REMARK 900 RELATED ID: 2PDN RELATED DB: PDB REMARK 900 RELATED ID: 2PDP RELATED DB: PDB REMARK 900 RELATED ID: 2PDQ RELATED DB: PDB REMARK 900 RELATED ID: 2PDU RELATED DB: PDB REMARK 900 RELATED ID: 2PDW RELATED DB: PDB REMARK 900 RELATED ID: 2PDY RELATED DB: PDB
DBREF 2PDX A 0 315 UNP P15121 ALDR_HUMAN 1 316
SEQADV 2PDX ILE A 4 UNP P15121 LEU 5 CONFLICT SEQADV 2PDX ARG A 302 UNP P15121 SER 303 ENGINEERED SEQADV 2PDX ASP A 303 UNP P15121 CYS 304 ENGINEERED
SEQRES 1 A 316 MET ALA SER ARG ILE LEU LEU ASN ASN GLY ALA LYS MET SEQRES 2 A 316 PRO ILE LEU GLY LEU GLY THR TRP LYS SER PRO PRO GLY SEQRES 3 A 316 GLN VAL THR GLU ALA VAL LYS VAL ALA ILE ASP VAL GLY SEQRES 4 A 316 TYR ARG HIS ILE ASP CYS ALA HIS VAL TYR GLN ASN GLU SEQRES 5 A 316 ASN GLU VAL GLY VAL ALA ILE GLN GLU LYS LEU ARG GLU SEQRES 6 A 316 GLN VAL VAL LYS ARG GLU GLU LEU PHE ILE VAL SER LYS SEQRES 7 A 316 LEU TRP CYS THR TYR HIS GLU LYS GLY LEU VAL LYS GLY SEQRES 8 A 316 ALA CYS GLN LYS THR LEU SER ASP LEU LYS LEU ASP TYR SEQRES 9 A 316 LEU ASP LEU TYR LEU ILE HIS TRP PRO THR GLY PHE LYS SEQRES 10 A 316 PRO GLY LYS GLU PHE PHE PRO LEU ASP GLU SER GLY ASN SEQRES 11 A 316 VAL VAL PRO SER ASP THR ASN ILE LEU ASP THR TRP ALA SEQRES 12 A 316 ALA MET GLU GLU LEU VAL ASP GLU GLY LEU VAL LYS ALA SEQRES 13 A 316 ILE GLY ILE SER ASN PHE ASN HIS LEU GLN VAL GLU MET SEQRES 14 A 316 ILE LEU ASN LYS PRO GLY LEU LYS TYR LYS PRO ALA VAL SEQRES 15 A 316 ASN GLN ILE GLU CYS HIS PRO TYR LEU THR GLN GLU LYS SEQRES 16 A 316 LEU ILE GLN TYR CYS GLN SER LYS GLY ILE VAL VAL THR SEQRES 17 A 316 ALA TYR SER PRO LEU GLY SER PRO ASP ARG PRO TRP ALA SEQRES 18 A 316 LYS PRO GLU ASP PRO SER LEU LEU GLU ASP PRO ARG ILE SEQRES 19 A 316 LYS ALA ILE ALA ALA LYS HIS ASN LYS THR THR ALA GLN SEQRES 20 A 316 VAL LEU ILE ARG PHE PRO MET GLN ARG ASN LEU VAL VAL SEQRES 21 A 316 ILE PRO LYS SER VAL THR PRO GLU ARG ILE ALA GLU ASN SEQRES 22 A 316 PHE LYS VAL PHE ASP PHE GLU LEU SER SER GLN ASP MET SEQRES 23 A 316 THR THR LEU LEU SER TYR ASN ARG ASN TRP ARG VAL CYS SEQRES 24 A 316 ALA LEU LEU ARG ASP THR SER HIS LYS ASP TYR PRO PHE SEQRES 25 A 316 HIS GLU GLU PHE
HET NAP A 500 48 HET ZST A 600 29
HETNAM NAP NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE HETNAM ZST 3,4-DIHYDRO-4-OXO-3-((5-TRIFLUOROMETHYL-2- HETNAM 2 ZST BENZOTHIAZOLYL)METHYL)-1-PHTHALAZINE ACETIC ACID
HETSYN NAP 2'-MONOPHOSPHOADENOSINE 5'-DIPHOSPHORIBOSE
FORMUL 2 NAP C21 H28 N7 O17 P3 FORMUL 3 ZST C19 H12 F3 N3 O3 S FORMUL 4 HOH *275(H2 O)
HELIX 1 1 PRO A 23 GLY A 38 1 16 HELIX 2 2 ALA A 45 GLN A 49 5 5 HELIX 3 3 ASN A 50 GLU A 64 1 15 HELIX 4 4 LYS A 68 LEU A 72 5 5 HELIX 5 5 TRP A 79 HIS A 83 5 5 HELIX 6 6 GLU A 84 GLY A 86 5 3 HELIX 7 7 LEU A 87 LYS A 100 1 14 HELIX 8 8 ASN A 136 GLU A 150 1 15 HELIX 9 9 ASN A 162 ASN A 171 1 10 HELIX 10 10 GLN A 192 LYS A 202 1 11 HELIX 11 11 ASP A 230 HIS A 240 1 11 HELIX 12 12 THR A 243 GLN A 254 1 12 HELIX 13 13 THR A 265 LYS A 274 1 10 HELIX 14 14 SER A 281 SER A 290 1 10
SHEET 1 A 2 ARG A 3 LEU A 5 0 SHEET 2 A 2 LYS A 11 PRO A 13 -1 O MET A 12 N ILE A 4 SHEET 1 B 8 GLY A 16 GLY A 18 0 SHEET 2 B 8 HIS A 41 ASP A 43 1 O ASP A 43 N LEU A 17 SHEET 3 B 8 PHE A 73 LEU A 78 1 O VAL A 75 N ILE A 42 SHEET 4 B 8 LEU A 106 ILE A 109 1 O LEU A 108 N LEU A 78 SHEET 5 B 8 ILE A 156 SER A 159 1 O GLY A 157 N ILE A 109 SHEET 6 B 8 VAL A 181 GLU A 185 1 O VAL A 181 N ILE A 158 SHEET 7 B 8 VAL A 205 TYR A 209 1 O TYR A 209 N ILE A 184 SHEET 8 B 8 VAL A 258 VAL A 259 1 O VAL A 258 N ALA A 208
SITE 1 AC1 31 GLY A 18 THR A 19 TRP A 20 LYS A 21 SITE 2 AC1 31 ASP A 43 TYR A 48 HIS A 110 TRP A 111 SITE 3 AC1 31 SER A 159 ASN A 160 GLN A 183 TYR A 209 SITE 4 AC1 31 SER A 210 PRO A 211 LEU A 212 GLY A 213 SITE 5 AC1 31 SER A 214 PRO A 215 ASP A 216 ALA A 245 SITE 6 AC1 31 ILE A 260 PRO A 261 LYS A 262 SER A 263 SITE 7 AC1 31 THR A 265 ARG A 268 GLU A 271 ASN A 272 SITE 8 AC1 31 HOH A 656 HOH A 684 HOH A 753 SITE 1 AC2 14 TRP A 20 TYR A 48 HIS A 110 TRP A 111 SITE 2 AC2 14 THR A 113 PHE A 122 TRP A 219 CYS A 298 SITE 3 AC2 14 LEU A 300 LEU A 301 THR A 304 TYR A 309 SITE 4 AC2 14 PRO A 310 HOH A 691
CRYST1 49.290 67.260 47.800 90.00 91.40 90.00 P 1 21 1 2
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.020288 0.000000 0.000496 0.00000
SCALE2 0.000000 0.014868 0.000000 0.00000
SCALE3 0.000000 0.000000 0.020927 0.00000